Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
These real-world findings are consistent with potential safety advantages of apixaban over warfarin and rivaroxaban for patients with atrial fibrillation and severe chronic kidney disease. Further randomized trials comparing individual oral anticoagulants are warranted.
Authors
- Alex R. Chang (ORCID: https://orcid.org/0000-0002-8114-7447)
- Morgan E. Grams (ORCID: https://orcid.org/0000-0002-4430-6023)
- Jung‐Im Shin (ORCID: https://orcid.org/0000-0003-0374-6927)
- Lesley A. Inker (ORCID: https://orcid.org/0000-0003-2820-9482)
- Yunwen Xu (ORCID: https://orcid.org/0000-0002-5946-2272)
- Shoshana H. Ballew (ORCID: https://orcid.org/0000-0002-7547-3764)
Institutions
- Tufts Medical Center (US)
- Johns Hopkins University (US)
- Geisinger Health System (US)
- New York University (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1161/jaha.123.034641
- Citations
- 10
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.02